No Data
No Data
EyePoint: JPMorgan, Citigroup Among Managers for Offering >EYPT
EyePoint to Use Net Proceeds From Offering to Advance Clinical Development of Duravyu for Wet Age Related Macular Degeneration, Diabetic Macular Edema >EYPT
EyePoint Pharmaceuticals Grants Underwriters Option for Additional 1.9M Shares >EYPT
Scotiabank Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $18
EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital
EyePoint Pharmaceuticals Analyst Ratings
No Data
No Data
IDKWTFIMDOING : That'll close in 2-3 days.
103418538 : is it a good news?
Trytosaveabit OP 103418538 : Not good for price short term!
IDKWTFIMDOING : No....but a good dip to buy.